LASTING TICK PROTECTION FOR DOGS

12-Week Clinical Evaluation Results

Bravecto efficacy was evaluated in a 12-week in a clinical field study. Results found that Bravecto has a ≥93.3% effectiveness for 12 weeks against Ixodes scapularis (black-legged tick), Dermacentor variabilis (American dog tick), and Rhipicephalus sanguineus (brown dog tick) and ≥90% effectiveness for 8 weeks against Amblyomma americanum (lone star tick).² Bravecto was also shown to reduce exposure to ticks, which can carry tick-borne diseases.